Showing 48 of 48 results

Peter Smith, Ashley Birkett, Charles Mgone
Ashley Birkett (Malaria Vaccine Initiative), Peter Smith (LSHTM)
Eusebio Macete
Plenary presentation
Organisation Mondiale de la Santé (OMS)
Conformément à son mandat, qui prévoit qu’elle conseille les États Membres en matière de politique sanitaire, l’OMS publie une série de notes de synthèse régulièrement mises à jour sur...
World Health Organization (WHO)
This market study was initiated in order to help establish a common understanding of the malaria vaccine market in the near and long term (2022-2036) and to support timely access to the vaccine...
Melissa Kapulu, KEMRI-Wellcome Trust Research Programme
Role of CHMI in malaria vaccine development, rationale for human infection studies in semi-immune adults in Kenya, work in progress and future developments
World Health Organization (WHO)
Q&A on the Phase 3 trial results for malaria vaccine RTS,S/AS01
World Health Organization (WHO)
Q&A on the malaria vaccine implementation programme (MVIP)
World Health Organization (WHO)
A first generation vaccine known as RTS,S/AS01 (RTS,S) acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine provides partial...
World Health Organization (WHO)
The World Malaria Report 2017 draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held...
Mahamadou S Sissoko et al.
Background: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P...
Li Liu et al.
Background Despite remarkable progress in the improvement of child survival between 1990 and 2015, the Millennium Development Goal (MDG) 4 target of a two-thirds reduction of under-5 mortality rate...
World Health Organization (WHO)
The World Malaria Report 2016 summarizes information received from malaria-endemic countries and other sources, and updates the analyses presented in the 2015 report. The World Malaria Report is...
Katya Galactionova et al.
Background RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention...
Lucas Otieno et al.
Malaria remains a major global public health concern, especially in sub-Saharan Africa. The RTS,S/AS01 malaria candidate vaccine was reviewed by the European Medicines Agency and received a positive...
Ally Olotu, Marc Lievens, Amanda Leach, George Nyangweso, Juliana Wambua, Gregory Fegan, Philip Bejon, Kevin Marsh, Patricia Njuguna, David C. Kaslow
RTS,S/AS01 is a malaria vaccine candidate that has undergone phase 3 evaluation across several sites in Africa that have varying intensities of malaria transmission. During more than 48 months of...
Sophie Githinji et al.
Health facility stock-outs of life saving malaria medicines are common across Africa. Innovative ways of addressing this problem are urgently required. We evaluated whether SMS based reporting of...
Since the 1915 launch of the first international eradication initiative targeting a human pathogen, much has been learned about the determinants of eradicability of an organism. The authors outline...
USAID - Deliver Project
Guidelines for Managing the Malaria Supply Chain: A Companion to the Logistics Handbook is a practical guidebook on supply chain management with an emphasis on antimalarial health products. The text...
World Health Organization (WHO)
In May 2015, the World Health Assembly endorsed a new Global Technical Strategy for Malaria. The strategy includes ambitious goals for malaria control and elimination in the next 15-year period. A...
Gretchen Newby et al.
n the past several years, as worldwide morbidity and mortality due to malaria have continued to decrease, the global malaria community has grown increasingly supportive of the idea of malaria...
Crawley et al.
Intermittent preventive treatment for malaria during infancy (IPTi) is the administration of a full therapeutic course of antimalarial drugs to infants living in settings where malaria is endemic, at...
World Health Organization (WHO)
This is the first WHO position paper on a malaria vaccine. It focuses primarily on the available evidence concerning the only candidate malaria vaccine to have received a positive regulatory...
Melissa A Penny et al.
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact...
Lonzozou Kpanake et al.
The diversity of parental positions regarding vaccinating their infants against malaria implies that malaria vaccination campaigns in Togo, and possibly in other sub-Saharan African countries, must...
Alassane Dicko, Ogobara Doumbo
Malaria vaccine research has been intensified over the past few years with several vaccines tested in trials. RTS,S vaccine has been the most promising of these candidates. The vaccine consists of P...
Joseph J. Campo et al.
A primary concern for the RTS,S malaria vaccine candidate is duration of protection. The ongoing Phase III trial reported evidence of waning efficacy within the first year following vaccination....
Subathra Devi C et al.
P. falciparum is highly virulent in nature because of its the ability to modify the infected host red blood cells, adherence to the vascular endothelium and changes in antigenicity at different...
Nicola K. Viebig et al.
The deployment of a safe and effective malaria vaccine will be an important tool for the control of malaria and the reduction in malaria deaths. With the launch of the 2030 Malaria Vaccine Technology...
Maokola W et al.
Electronic data capture took place in 11 sentinel health centres in rural southern Tanzania. Information from children attending the outpatient department (OPD) and the Expanded Program on...
Anna M. Winters, David A. Larsen, Jessie Pinchoff, Brian Chirwa, Daniel J. Bridges, Derek Pollard , Silvia Renn, Aniset Kamanga
BACKGROUND: Defining the number and location of sprayable structures (houses) is foundational to plan and monitor indoor residual spray (IRS) implementation, a primary intervention used to control...
Selidji Todagbe Agnandji et al.
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. The researchers...
The malERA Consultative Group on Vaccines
Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing...
Roma Chilengicorresponding and Jesse Gitaka
Malaria remains a major health burden especially for the developing countries. Despite concerted efforts at using the current control tools, such as bed nets, anti malarial drugs and vector control...
Grace Mwangoka et al.
Malaria vaccines are considered amongst the most important modalities for potential elimination of malaria disease and transmission. Research and development in this field has been an area of intense...
VS Moorthy et al.
No licensed vaccines are available for malaria or any other human parasitic disease. The most advanced malaria vaccine candidate is RTS,S/AS01, which is directed against Plasmodium falciparum...
Julie Milstien et al.
This article analyses the WHO policy development process to predict its course for a malaria vaccine.
Geoffrey AT Targett
The WHO Malaria Advisory Committee (MALVAC) provides advice to WHO on strategic priorities, activities and technical issues related to global efforts to develop vaccines against malaria. MALVAC...
Susanna Dunachie et al.
A vaccine for malaria is urgently required. The RTS,S vaccine represents major progress, but is only partially effective. Development of the next generation of highly effective vaccines requires...